

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Wednesday, April 10, 2024

How to Use this Report:

1. Check your genomic testing report (e.g., TEMPUS, FoundationOne, Caris, etc.) to see if your tumor has one of the genomic alterations listed in the left-hand column.

Note: If you are not sure if you have had genomic testing on your tumor, please contact your oncologist.

2. Determine whether any of your genomic alterations are listed in the left-hand column.

3. Review the right-hand column to determine if your type of cancer is listed beside it.

4. A patient may be eligible for more than one genomic alteration and cancer type combination. Please review this report in its entirety.

5. A patient must be deemed eligible based on general and drug specific eligibility criteria reviewed during screening procedures.

6. Contact a TAPUR Study clinical site for more information by visiting TAPUR.org/map which will help you to find the location closest to you.

PLEASE NOTE: This report updates daily. A match appearing on this list does not guarantee it will be available once screening procedures have been completed.

Drug=Abemaciclib (VERZENIO)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CCNE1 amplification	Esophagus Cancer
CDK4 amplification	Any solid tumor
CDK6 amplification	Any solid tumor
CDKN2A loss or mutation	Bladder Cancer
	Bone and Cartilage Cancer
	Cancer of the small intestine
	Cervical Cancer
	Colorectal cancer
	Head and Neck Cancer
	Melanoma
	Prostate Cancer
	Soft tissue sarcoma
	Squamous cell carcinoma
	Stomach Cancer
	Thymus Cancer
	Urinary Organ Cancer
CDKN2B loss or mutation	Any solid tumor

Drug=Atezolizumab (TECENTRIQ) + PHESGO

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
ERBB2 amplification or overexpression	Any solid tumor

Drug=Atezolizumab (TECENTRIQ) + Talazoparib (TALZENNA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
Positive genomic instability (GI) score or genomic loss of heterozygosity (LOH) score above threshold	Any solid tumor except Colorectal cancer

Drug=Cobimetinib (COTELLIC) + Vemurafenib (ZELBORAF)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
BRAF_V600E/D/K/R mutation	Cancer of Gallbladder and Bile Ducts
	Thyroid Cancer

Drug=Entrectinib (ROZLYTREK)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
ROS1 fusion	Any solid tumor except Non-Small Cell Lung Cancer (NSCLC)

Drug=Futibatinib (LYTGObI)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR1 fusion, rearrangement, or mutation	Lung Cancer
	Nervous System Cancer
	Pancreatic Cancer

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Wednesday, April 10, 2024

Drug=Futibatinib (LYTGOBI)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR2 fusion, rearrangement, or mutation	Ovarian Cancer
	Pancreatic Cancer
	Squamous cell carcinoma
	Uterine Cancer
FGFR3 fusion, rearrangement, or mutation	Bone and Cartilage Cancer
	Colorectal cancer
	Lung Cancer
	Stomach Cancer

Drug=Larotrectinib (VITRAKVI)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
NTRK1/NTRK2/NTRK3 amplification	Any solid tumor

Drug=Palbociclib (IBRANCE)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CDKN2A loss or mutation	Bone and Cartilage Cancer
	Soft tissue sarcoma

Drug=Pertuzumab (PERJETA) + Trastuzumab (HERCEPTIN)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
ERBB2/ERBB3 mutation	Any solid tumor except Colorectal cancer, Esophagus Cancer, Peritoneal and Retroperitoneal Cancer, Testicular Cancer, Thymus Cancer, Vaginal Cancer
ERBB2/ERBB3 mutation or ERBB3 amplification	Breast Cancer

Drug=Pertuzumab (PERJETA) + Trastuzumab (HERCEPTIN)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
ERBB2/ERBB3 mutation, amplification or overexpression	Head and Neck Cancer
	Pancreatic Cancer
	Stomach Cancer

Drug=Regorafenib (STIVARGA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
BRAF mutation or amplification	Lung Cancer
KIT mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma
PDGFR β mutation, amplification, or overexpression	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma
RAF-1 mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma
VEGFR2 (KDR) mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma
VEGFR3 (FLT-4) mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Wednesday, April 10, 2024

Drug=Sunitinib (SUTENT)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR1 mutation or amplification	Colorectal cancer
FGFR2 mutation or amplification	Cancer of Gallbladder and Bile Ducts
FGFR3 mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
FLT-3 mutation or amplification	Any solid tumor except Colorectal cancer, Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors (pNET)
KIT mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
PDGFRA mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
PDGFR β mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
RET mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
VEGFR2 (KDR) mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
VHL mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET

Drug=Talazoparib (TALZENNA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CHEK2 mutation	Any solid tumor
PALB2 mutation	Any solid tumor except Breast Cancer, Prostate Cancer

Drug=Temsirolimus (TORISEL)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
TSC1 mutation	Any solid tumor except Renal Cell Carcinoma (RCC)
TSC2 mutation	Any solid tumor except Renal Cell Carcinoma (RCC)

Drug=Tucatinib (TUKYSA) + Trastuzumab SC (HERCEPTIN SC)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
ERBB2 mutation, amplification or overexpression	Any solid tumor except Colorectal cancer, Breast Cancer, Gastric cancer, Gastroesophageal cancer